Open AccessPancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
Author(s) -
Mariacristina Di Marco,
Riccardo Carloni,
Stefania De Lorenzo,
Cristina Mosconi,
Andrea Palloni,
Elisa Grassi,
Daria Maria Filippini,
Angela Dalia Ricci,
Alessandro Rizzo,
Alessandro Di Federico,
Donatella Santini,
Daniela Turchetti,
Claudio Ricci,
Carlo Ingaldi,
Laura Alberici,
Francesco Minni,
Rita Golfieri,
Giovanni Brandi,
Riccardo Casadei
Publication year - 2020
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v12.i12.1456
Subject(s) - olaparib , medicine , germline , mucinous cystadenocarcinoma , germline mutation , mutation , cancer research , brca mutation , cystadenocarcinoma , oncology , ovarian cancer , pancreas , genetics , cancer , dna , gene , biology , polymerase , poly adp ribose polymerase
Pancreatic mucinous cystadenocarcinoma (MCAC) is a rare malignancy with a poor prognosis when it presents metastases at diagnosis. Due to its very low incidence, there are no clear recommendations for the treatment of advanced disease. Olaparib (an oral PARP inhibitor) has been approved for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma harbouring germline BRCA1 / 2 mutations. Herein, we report the first case of a germline BRCA1 mutated unresectable MCAC which was effectively treated with olaparib.